NCT06406348View on ClinicalTrials.gov

A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

April 22, 2025

Study Completion Date

April 22, 2025

Conditions
Alzheimer Disease
Interventions
DRUG

ALIA-1758

Intravenous or subcutaneous doses

OTHER

Placebo

Intravenous or subcutaneous doses

Trial Locations (1)

78217

Worldwide Clinical Trials Early Phase Services, LLC, San Antonio

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY